Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Agenus Inc.

< Previous 1 2 Next >
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports First Quarter 2024 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Reverse Stock Split of Common Stock
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Fourth Quarter and Full Year 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in Leerink Partners Global Biopharma Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in B. Riley Healthcare Conference
From Agenus Inc.
Via Business Wire
Tickers AGEN
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Third Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
From Agenus Inc.
Via Business Wire
Tickers AGEN
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus To Host BOT/BAL Program Update at ESMO 2023
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Reports Second Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Tickers AGEN
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
From Agenus Inc.
Via Business Wire
Tickers AGEN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.